Transcode Therapeutics Inc Total Liabilities
Transcode Therapeutics Inc total liabilities. Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) has total liabilities worth $12.65 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Transcode Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Transcode Therapeutics Inc (2018–2025)
Total liabilities of Transcode Therapeutics Inc from 2018 to 2025. This chart illustrates how Transcode Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
Transcode Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Transcode Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TROC DE L'ILE SA
PA:MLTRO
|
France | €2.65 Million |
|
Haoxin Holdings Limited Class A Ordinary Shares
NASDAQ:HXHX
|
USA | $22.65 Million |
|
Golden Sun Education Group Ltd
NASDAQ:GSUN
|
USA | $9.67 Million |
|
TECIL Chemicals and Hydro Power Limited
NSE:TECILCHEM
|
India | Rs230.03 Million |
|
MOBA Network publ AB
ST:MOBA
|
Sweden | Skr357.78 Million |
|
Hepion Pharmaceuticals Inc
NASDAQ:HEPA
|
USA | $402.40K |
|
Vertical Explorations Inc
V:VERT
|
Canada | CA$988.15K |
|
Smtrack Bhd
KLSE:0169
|
Malaysia | RM23.76 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Transcode Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RNAZ asset base.
Liquidity & Leverage Metrics
Transcode Therapeutics Inc Total Liabilities Ratios Explained
Transcode Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Transcode Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Transcode Therapeutics Inc (2018–2025)
The table below shows the annual total liabilities of Transcode Therapeutics Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $152.06 Million | +1532.77% |
| 2024-12-31 | $9.31 Million | +163.91% |
| 2023-12-31 | $3.53 Million | -18.83% |
| 2022-12-31 | $4.35 Million | +71.55% |
| 2021-12-31 | $2.53 Million | -43.23% |
| 2020-12-31 | $4.46 Million | +239.63% |
| 2019-12-31 | $1.31 Million | +82.89% |
| 2018-12-31 | $718.61K | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastati… Read more